Dear Doctor,

Re: Discontinuation of Humulin®U ULTRALENTE® (HUMAN INSULIN [rDNA ORIGIN] EXTENDED ZINC SUSPENSION) and Humulin®L LENTE® (HUMAN INSULIN [rDNA ORIGIN] ZINC SUSPENSION)

After thoughtful consideration, Eli Lilly and Company has decided to stop producing Humulin U and Humulin L Insulins. Use of these longer-acting insulins has declined by more than 70% over the past five years due to newer insulin therapies that have increased the number of treatment options for patients. It is currently estimated that less than 2% of the patients with diabetes who use insulin in the U.S. will be impacted by this discontinuation.

Our first priority is to make certain that patients transition as smoothly as possible to an alternative insulin therapy, regardless of whether the new therapy is a Lilly insulin or not. Lilly is notifying physicians, other healthcare professionals, diabetes associations, and patients regarding the timing for the discontinuation to allow affected patients sufficient time to transfer to alternate insulin formulations or treatments.

Based on current patient demand levels and our current stock of insulin, Lilly anticipates that vials of both products will be available at pharmacies until the end of 2005. All vials of both Humulin U and Humulin L Insulin shipped from Lilly after mid-August 2005 will have the following notice printed on the carton: ULTRALENTE® and LENTE® Human Insulin (rDNA origin) zinc suspension (are) being discontinued. Contact your physician to change to another insulin. For information call 1-800-545-5979.

Lilly is recommending to patients who are currently using Humulin U or Humulin L Insulin that they see their physician so that appropriate changes to their insulin treatment can be made. Healthcare providers should consider switching patients to NPH human insulin or a basal insulin analog. Careful monitoring of blood glucose levels and adjustments to insulin therapy are important when switching patients, in addition to the other standard recommendations concerning diabetes care(1).

To assist you in communicating information concerning this product discontinuation to your patients who use Humulin U and Humulin L Insulins, enclosed are copies of the patient information sheet. The sheet will inform patients about the discontinuation and provide answers to frequently asked questions. To avoid confusion, please be sure to distribute the sheet only to patients currently using Humulin U and Humulin L Insulins. Also enclosed are 5 LillyScripts for redemption on any Lilly insulin product to help facilitate transition of affected patients.

You can also find the patient information sheets online. Physicians can visit www.LillyConnect.com and direct patients to www.LillyDiabetes.com.

Again, Lilly's first priority is to make certain that patients transition as smoothly as possible to an alternative insulin therapy, regardless of whether the new therapy is a Lilly insulin or not.

For additional information, Lilly is available to answer your questions at 1-800-LillyRx (1-800-545-5979) from 9:00am to 5:00pm Eastern Time, Monday through Friday.

Sincerely,



Scott Jacober, DO, FACE
Medical Advisor
Diabetes Care
Eli Lilly and Company
Indianapolis, Indiana

1. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. *Diabetes Care.* 2005; 28 (suppl 1); S4-36.